ASTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Astrana Health Inc (ASTH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows strong revenue growth, its declining net income and EPS, coupled with bearish technical indicators, suggest caution. The lack of recent positive news, no significant insider or hedge fund activity, and neutral trading sentiment further support a hold recommendation.
The technical indicators are bearish. The MACD is negatively expanding, RSI is neutral at 53.104, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 24.24, with support at 23.321 and resistance at 25.158. Overall, there is no clear bullish signal.
Revenue growth of 42.89% YoY in Q4 2025 indicates strong top-line performance. Analysts maintain a Buy rating with a raised price target by Truist to $38, citing the company's emergence as a larger value-based care platform.
Net income dropped by -186.30% YoY, and EPS fell by -180.00% YoY in Q4 2025, raising concerns about profitability. No recent news or significant insider/hedge fund activity. Technical indicators are bearish, and the stock has a low probability of significant short-term gains.
In Q4 2025, revenue increased by 42.89% YoY to $950.53M, but net income dropped by -186.30% YoY to $5.99M. EPS fell by -180.00% YoY to 0.12. Gross margin improved by 29.83% YoY to 8.27, but profitability remains a concern.
Analysts maintain a Buy rating. Truist raised the price target to $38, citing the company's growth potential as a value-based care platform. However, BTIG lowered its price target to $40, citing macro challenges and high medical trends impacting the sector.
